Quick Dispatch:
Your surmount-osa tirzepatide results Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-osa tirzepatide results Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity ships.
Need Help?
Questions about surmount-osa tirzepatide results Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-osa tirzepatide results Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity in your area.
Eli Lilly announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI)
24.06
In the two SURMOUNT-OSA trials, researchers assessed the efficacy and safety of tirzepatide for the treatment of adults with obstructive sleep apnea and obesity. Full results of both trials and Plain Language
20.18
Tirzepatide
20.27
SURMOUNT-3 study design This is a phase 3, multicenter, randomized,
27.05
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial
21.23
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
21.36
GLP-1 for Sleep Apnea — What the Data Shows
27.04
